Quick Answer
Decoy Therapeutics Inc. reported Operating Income Loss of -$12.61 million for the year ending 2025.
- Decoy Therapeutics Inc. showed a decrease of -120.0% in Operating Income Loss from 2024 to 2025.
- This data is from Decoy Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), Decoy Therapeutics Inc.'s Operating Income Loss has grown by 56.8%.
- Historical annual values: Fiscal year 2025: -$12.61 million | Fiscal year 2024: -$5.73 million | Fiscal year 2023: -$12.89 million | Fiscal year 2022: -$31.84 million | Fiscal year 2021: -$12.81 million | Fiscal year 2020: -$7.79 million | Fiscal year 2019: -$8.27 million | Fiscal year 2018: -$1.68 million | Fiscal year 2017: -$34.73 million | Fiscal year 2016: -$39.89 million | Fiscal year 2015: -$29.21 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: